Objective: To investigate the impact of preoperative serum C-reactive protein (CRP) on clinicopathological features and prognosis in patients with upper tract urothelial cancer (UTUC) after radical nephroureterectomy (RNU). Patients and Methods: Data of 265 patients from three German centers who underwent RNU for UTUC without neoadjuvant chemotherapy between 1990 and 2012 were evaluated. Mean follow-up was 37 months (interquartile range 9-48). CRP was analyzed as a categorical and continuous variable for the prediction of recurrence-free survival (RFS), disease-specific survival (DSS) and all-cause survival (ACS) using uni- and multivariate Cox regression analyses. Results: The optimal cutoff for CRP was calculated by the Youden index at 0.90 mg/dl. Elevated CRP was significantly associated with pT3/4 and pN+ in a preoperative model including age, gender, tumor multifocality, tumor localization and the Eastern Cooperative Oncology Group Performance Status. In a multivariable Cox regression model adjusted for features significant in univariable analysis, categorized and continuous CRP levels were both independent predictors for RFS [hazard ratio (HR) 1.18, p = 0.050; HR 1.03, p = 0.012] and DSS (HR 1.61, p = 0.026; HR 1.06, p = 0.001). Continuous CRP was an independent predictor for ACS (HR 1.05, p = 0.036). Conclusions: Elevated preoperative CRP is significantly associated with aggressive tumor biology and an independent predictor for poor survival after RNU. Preoperative serum CRP represents an easily obtainable and cost-effective marker in UTUC and may help in counseling patients with regard to operative management and/or adjuvant or neoadjuvant therapies.

Keywords:
C-reactive protein, Upper tract urothelial carcinoma, Nephroureterectomy, Prognosis, Survival
1.
Rouprêt M, Babjuk M, Compérat E, et al: European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013;63:1059-1071.
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3.
Margulis V, Shariat SF, Matin SF, et al; Upper Tract Urothelial Carcinoma Collaboration: Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224-1233.
4.
Lughezzani G, Burger M, Margulis V, et al: Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012;62:100-114.
5.
Cho DS, Kim SI, Ahn HS, Kim SJ: Predictive factors for bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Int 2013;91:153-159.
6.
Kuroda K, Asakuma J, Horiguchi A, et al: Prognostic factors for upper urinary tract urothelial carcinoma after nephroureterectomy. Urol Int 2012;88:225-231.
7.
Jang NY, Kim IA, Byun SS, Lee SE, Kim JS: Patterns of failure and prognostic factors for locoregional recurrence after radical surgery in upper urinary tract transitional cell carcinoma: implications for adjuvant radiotherapy. Urol Int 2013;90:202-206.
8.
Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ: Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 2013;91:291-296.
9.
Gakis G, Todenhöfer T, Renninger M, et al: Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011;108:1800-1805.
10.
Saito K, Kihara K: C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011;8:659-666.
11.
Saito K, Kawakami S, Ohtsuka Y, et al: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007;100:269-273.
12.
Obata J, Kikuchi E, Tanaka N, et al: C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol 2013;31:1725-1730.
13.
Stein B, Schrader AJ, Wegener G, et al: Preoperative serum C-reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer 2013;13:101.
14.
Tanaka N, Kikuchi E, Shirotake S, et al: The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study. Eur Urol 2014;65:227-234.
15.
Rink M, Ehdaie B, Cha EK, et al: Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 2012;62:677-684.
16.
Rink M, Robinson BD, Green DA, et al: Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 2012;188:398-404.
17.
Chromecki TF, Cha EK, Fajkovic H, et al: The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 2012;61:245-253.
18.
Edge SB, Byrd DR, Compton CC, et al: American Joint Committee on Cancer (AJCC) Staging Manual. New York, Springer, 2010.
19.
Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
20.
Remzi M, Haitel A, Margulis V, et al: Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009;103:307-311.
21.
Kikuchi E, Margulis V, Karakiewicz P, et al: Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 2009;27:612-618.
22.
Rink M, Fajkovic H, Cha EK, et al: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012;61:854-855.
23.
Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
24.
Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2006;99:77-80.
25.
Gakis G, Todenhöfer T, Stenzl A: The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol 2011;21:428-433.
26.
Kinoshita T, Ito H, Miki C: Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1998;85:2526-2531.
27.
McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91:1993-1995.
28.
Du Clos TW, Mold C: C-reactive protein. An activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004;30:261-277.
29.
Canna K, McArdle PA, McMillan DC, et al: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005;92:651-654.
30.
Mancino A, Lawrence T: Nuclear factor-kappaB and tumour-associated macrophages. Clin Cancer Res 2010;6:784-789.
31.
Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumour microenvironment. Cancer Cell 2012;21:309-322.
32.
Weis SM, Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-1370.
33.
McMillan DC, Scott HR, Watson WS, et al: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998;31:101-105.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.